Oura, the Finnish company behind the smart ring, announced today that it has closed a $200 million Series D at a $5.2 billion valuation, with Fidelity and the glucose-sensor maker Dexcom participating. The ring measures pulse, temperature and movement, infers how long you spent in each stage of sleep, and turns the night into a score you check before you have spoken to anyone. One of us owned the first generation; the fourth shipped in October. The question worth asking of a $5.2 billion valuation is what, exactly, is being valued.
What the business is. Hardware plus a subscription, which means the product is the habit of checking. Oura's own announcement says the ring is not a medical device and is not intended to diagnose or treat anything. A finger sensor cannot see your brain; it infers sleep stages from pulse, temperature and movement, and sleep clinicians treat those inferences as estimates rather than measurements. None of that makes the ring useless. It makes the score a weather report, not a diagnosis, and it makes the valuation a bet on how many people will look at the weather every morning.
Ben’s takeI wore one for years and programmed a watch to wake me at the moment the ring's data said my sleep cycle ended. My heart-rate variability — a measure the ring itself reports — declined for months while I did it. The ring was not wrong. It was telling me the optimization was the problem, and I kept checking the score instead of hearing it. As a business, $5.2 billion makes sense: recurring revenue, a daily habit, a dashboard. As a health claim it tells you nothing, and the company, to its credit, does not pretend otherwise. As far as we can find, no consumer wearable has shown a mortality benefit, and none claims one.
Loree’s takeSleep clinicians have a name for anxiety caused by a sleep tracker: orthosomnia. I see it weekly. The ring reports forty-two minutes of deep sleep; the patient spends the day worried about it; the worry costs deep sleep the next night. The data is not the problem. Reading it before breakfast is.
What to watch. The Dexcom partnership announced alongside the round will put continuous glucose readings in the ring's app — for people who do not have diabetes. That is a second daily number to worry about, and a second subscription, layered on the first. Watch how it is marketed: a glucose curve in a healthy person moves with every meal, every walk and every bad night, and the people best positioned to sell you a reading are not the people best positioned to tell you it is normal.
Take the ring off for a week. If you sleep the same, you have learned what it was for.